uniQure (NASDAQ:QURE) Shares Climb 6.9% - What's Next?

Key Points

• uniQure shares rose 6.9% to $26.21 after the company reported encouraging 36-month AMT-130 data showing substantial slowing of Huntington’s disease progression; the FDA has indicated this data may support an accelerated-approval review.
• Longer-term results were mixed: 48-month TFC data showed a 61% slowing of decline, but the key cUHDRS endpoint showed a non-statistically significant 44% slowing, raising concerns about durability and approval prospects.
• Wall Street remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $58.18, although securities-law investigations and reported insider selling add risk.

uniQure N.V. (NASDAQ:QURE - Get Free Report) traded up 6.9% during trading on Wednesday. The company traded as high as $26.68 and last traded at $26.21. 1,367,283 shares were traded during trading, a decline of 44% from the average daily volume of 2,428,466 shares. The stock had previously closed at $24.51.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The company said its 36-month analysis, which supports its submitted Biologics License Application, showed an 80% slowing of disease progression on cUHDRS and a 67% slowing on Total Functional Capacity (TFC). The FDA has indicated that the 36-month data can serve as the primary basis for an accelerated-approval review. uniQure Announces Additional Data from Ongoing Phase I/II Studies
• Positive Sentiment: At 48 months, TFC still showed a 61% slowing of functional decline, and the company reported a dose-dependent benefit. uniQure also argued that missing data and survivor bias in the external-control group may have understated AMT-130’s effect, while maintaining that the regulatory pathway remains viable. UniQure Insists Huntington's Drug Is Still on Track
• Neutral Sentiment: Unusually heavy options activity preceded the data release, with traders buying roughly 35,700 call options—about 488% of typical volume—indicating elevated speculative interest but not a clear directional signal.
• Negative Sentiment: The key 48-month cUHDRS endpoint showed only 44% slowing and was not statistically significant (p=0.144), compared with the stronger earlier results. Investors viewed the weaker long-term signal as a setback for confidence in AMT-130’s durability and approval prospects. UniQure's Huntington's Therapy Fails to Significantly Slow Disease Progression
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following the data disclosure, adding legal and reputational overhang. Reports also noted extensive insider selling over the past six months, although those transactions may include scheduled sales. uniQure Investigation Notice

Wall Street Analysts Forecast Growth

QURE has been the subject of a number of recent research reports. HC Wainwright restated a "buy" rating on shares of uniQure in a report on Tuesday. Mizuho increased their target price on shares of uniQure from $35.00 to $68.00 and gave the company an "outperform" rating in a report on Thursday, June 25th. Wolfe Research upgraded shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 target price on the stock in a research report on Wednesday, July 29th. Leerink Partners boosted their price target on shares of uniQure from $36.00 to $70.00 and gave the stock an "outperform" rating in a research note on Thursday, June 18th. Finally, Wall Street Zen lowered shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $58.18.

uniQure Stock Up 3.5%

The stock's fifty day moving average is $44.25 and its 200 day moving average is $33.29. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.76 billion, a P/E ratio of -6.25 and a beta of 0.94.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the business earned ($0.69) EPS. Research analysts predict that uniQure N.V. will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, CEO Matthew Kapusta sold 21,082 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total transaction of $952,063.12. Following the completion of the sale, the chief executive officer directly owned 519,227 shares in the company, valued at approximately $23,448,291.32. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.65% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC grew its position in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company's stock worth $147,170,000 after buying an additional 1,705,556 shares during the last quarter. Orbimed Advisors LLC raised its holdings in shares of uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock valued at $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. Artia Global Partners LP lifted its stake in uniQure by 55.4% in the fourth quarter. Artia Global Partners LP now owns 1,023,539 shares of the biotechnology company's stock worth $24,493,000 after acquiring an additional 364,700 shares during the period. Assenagon Asset Management S.A. lifted its stake in uniQure by 249.9% in the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company's stock worth $23,653,000 after acquiring an additional 366,781 shares during the period. Finally, Fiera Capital Corp bought a new stake in uniQure in the fourth quarter valued at $18,390,000. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure's pipeline has included AMT-130, an investigational gene therapy for Huntington's disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.